About
Science
- PAM Pathway
- Publications
Pipeline
Clinical Trials
Investors
Careers

Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions

Post navigation

Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models

Search for:

Recent Posts

Developing first-in-class therapeutics using a 3rd generation diagnostic platform

Recent Comments

Archives

October 2021

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

16305 36th Avenue North
Minneapolis, MN 55446

Follow us on

in x

©2025 Celcuity Inc.

Privacy Policy Accessibility Statement